vs
Akebia Therapeutics, Inc.（AKBA）与READING INTERNATIONAL INC（RDI）财务数据对比。点击上方公司名可切换其他公司
Akebia Therapeutics, Inc.的季度营收约是READING INTERNATIONAL INC的1.1倍（$57.6M vs $50.3M），Akebia Therapeutics, Inc.同比增速更快（23.9% vs -14.2%），Akebia Therapeutics, Inc.自由现金流更多（$31.1M vs $4.1M），过去两年Akebia Therapeutics, Inc.的营收复合增速更高（32.9% vs 5.6%）
Akebia Therapeutics是一家专注于肾病领域的生物制药企业，核心业务覆盖药物研发、临床试验及商业化推广全流程，主要开发针对慢性肾病相关贫血等适应症的创新疗法，面向全球市场，致力于满足肾病治疗领域未被满足的临床需求。
雷丁公司是总部位于美国费城的铁路企业，1924年起在宾夕法尼亚州东部及周边各州提供客运与货运运输服务，直至1976年被联合铁路公司收购。
AKBA vs RDI — 直观对比
营收规模更大
AKBA
是对方的1.1倍
$50.3M
营收增速更快
AKBA
高出38.1%
-14.2%
自由现金流更多
AKBA
多$26.9M
$4.1M
两年增速更快
AKBA
近两年复合增速
5.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $57.6M | $50.3M |
| 净利润 | — | $-2.6M |
| 毛利率 | 78.2% | — |
| 营业利润率 | -14.8% | -1.9% |
| 净利率 | — | -5.1% |
| 营收同比 | 23.9% | -14.2% |
| 净利润同比 | — | -14.5% |
| 每股收益（稀释后） | $-0.05 | $-0.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AKBARDI
| Q4 25 | $57.6M | $50.3M | ||
| Q3 25 | $58.8M | $52.2M | ||
| Q2 25 | $62.5M | $60.4M | ||
| Q1 25 | $57.3M | $40.2M | ||
| Q4 24 | $46.5M | $58.6M | ||
| Q3 24 | $37.4M | $60.1M | ||
| Q2 24 | $43.6M | $46.8M | ||
| Q1 24 | $32.6M | $45.1M |
净利润AKBARDI
| Q4 25 | — | $-2.6M | ||
| Q3 25 | $540.0K | $-4.2M | ||
| Q2 25 | $247.0K | $-2.7M | ||
| Q1 25 | $6.1M | $-4.8M | ||
| Q4 24 | — | $-2.2M | ||
| Q3 24 | $-20.0M | $-7.0M | ||
| Q2 24 | $-8.6M | $-12.8M | ||
| Q1 24 | $-18.0M | $-13.2M |
毛利率AKBARDI
| Q4 25 | 78.2% | — | ||
| Q3 25 | 84.0% | — | ||
| Q2 25 | 84.1% | — | ||
| Q1 25 | 86.7% | — | ||
| Q4 24 | 56.2% | — | ||
| Q3 24 | 62.2% | — | ||
| Q2 24 | 60.9% | — | ||
| Q1 24 | 64.4% | — |
营业利润率AKBARDI
| Q4 25 | -14.8% | -1.9% | ||
| Q3 25 | 7.6% | -0.6% | ||
| Q2 25 | 22.6% | 4.8% | ||
| Q1 25 | 23.6% | -17.2% | ||
| Q4 24 | -30.8% | 2.6% | ||
| Q3 24 | -33.4% | -0.6% | ||
| Q2 24 | -20.0% | -16.4% | ||
| Q1 24 | -45.8% | -16.7% |
净利率AKBARDI
| Q4 25 | — | -5.1% | ||
| Q3 25 | 0.9% | -8.0% | ||
| Q2 25 | 0.4% | -4.4% | ||
| Q1 25 | 10.7% | -11.8% | ||
| Q4 24 | — | -3.8% | ||
| Q3 24 | -53.5% | -11.7% | ||
| Q2 24 | -19.7% | -27.4% | ||
| Q1 24 | -55.2% | -29.4% |
每股收益（稀释后）AKBARDI
| Q4 25 | $-0.05 | $-0.11 | ||
| Q3 25 | $0.00 | $-0.18 | ||
| Q2 25 | $0.00 | $-0.12 | ||
| Q1 25 | $0.03 | $-0.21 | ||
| Q4 24 | $-0.10 | $-0.11 | ||
| Q3 24 | $-0.10 | $-0.31 | ||
| Q2 24 | $-0.04 | $-0.57 | ||
| Q1 24 | $-0.09 | $-0.59 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $184.8M | $10.5M |
| 总债务越低越好 | $48.3M | $185.1M |
| 股东权益账面价值 | $32.6M | $-18.2M |
| 总资产 | $376.6M | $434.9M |
| 负债/权益比越低杠杆越低 | 1.48× | — |
8季度趋势，按日历期对齐
现金及短期投资AKBARDI
| Q4 25 | $184.8M | $10.5M | ||
| Q3 25 | $166.4M | $8.1M | ||
| Q2 25 | $137.3M | $9.1M | ||
| Q1 25 | $113.4M | $5.9M | ||
| Q4 24 | $51.9M | $12.4M | ||
| Q3 24 | $34.0M | $10.1M | ||
| Q2 24 | $39.5M | $9.3M | ||
| Q1 24 | $42.0M | $7.5M |
总债务AKBARDI
| Q4 25 | $48.3M | $185.1M | ||
| Q3 25 | $47.6M | — | ||
| Q2 25 | $47.1M | — | ||
| Q1 25 | $46.5M | — | ||
| Q4 24 | $38.7M | $202.7M | ||
| Q3 24 | $38.4M | — | ||
| Q2 24 | $38.0M | — | ||
| Q1 24 | $30.1M | — |
股东权益AKBARDI
| Q4 25 | $32.6M | $-18.2M | ||
| Q3 25 | $41.6M | $-12.1M | ||
| Q2 25 | $29.2M | $-7.7M | ||
| Q1 25 | $24.6M | $-8.1M | ||
| Q4 24 | $-49.2M | $-4.4M | ||
| Q3 24 | $-50.4M | $1.6M | ||
| Q2 24 | $-33.8M | $6.5M | ||
| Q1 24 | $-27.3M | $18.0M |
总资产AKBARDI
| Q4 25 | $376.6M | $434.9M | ||
| Q3 25 | $364.2M | $435.2M | ||
| Q2 25 | $345.6M | $438.1M | ||
| Q1 25 | $310.2M | $441.0M | ||
| Q4 24 | $220.7M | $471.0M | ||
| Q3 24 | $207.1M | $495.7M | ||
| Q2 24 | $220.2M | $494.9M | ||
| Q1 24 | $225.5M | $494.9M |
负债/权益比AKBARDI
| Q4 25 | 1.48× | — | ||
| Q3 25 | 1.15× | — | ||
| Q2 25 | 1.61× | — | ||
| Q1 25 | 1.89× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $31.1M | $4.3M |
| 自由现金流经营现金流 - 资本支出 | $31.1M | $4.1M |
| 自由现金流率自由现金流/营收 | 53.9% | 8.2% |
| 资本支出强度资本支出/营收 | 0.1% | 0.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $67.7M | $-2.9M |
8季度趋势，按日历期对齐
经营现金流AKBARDI
| Q4 25 | $31.1M | $4.3M | ||
| Q3 25 | $28.1M | $295.0K | ||
| Q2 25 | $22.3M | $1.6M | ||
| Q1 25 | $-13.6M | $-7.7M | ||
| Q4 24 | $-4.5M | $8.0M | ||
| Q3 24 | $-6.7M | $1.3M | ||
| Q2 24 | $-10.1M | $-10.4M | ||
| Q1 24 | $-19.4M | $-2.8M |
自由现金流AKBARDI
| Q4 25 | $31.1M | $4.1M | ||
| Q3 25 | $28.0M | $-246.0K | ||
| Q2 25 | $22.2M | $1.2M | ||
| Q1 25 | $-13.6M | $-8.0M | ||
| Q4 24 | $-4.5M | $7.0M | ||
| Q3 24 | $-6.7M | $-1.1M | ||
| Q2 24 | $-10.1M | $-10.6M | ||
| Q1 24 | — | $-4.7M |
自由现金流率AKBARDI
| Q4 25 | 53.9% | 8.2% | ||
| Q3 25 | 47.7% | -0.5% | ||
| Q2 25 | 35.6% | 1.9% | ||
| Q1 25 | -23.7% | -19.8% | ||
| Q4 24 | -9.6% | 12.0% | ||
| Q3 24 | -17.9% | -1.8% | ||
| Q2 24 | -23.1% | -22.7% | ||
| Q1 24 | — | -10.4% |
资本支出强度AKBARDI
| Q4 25 | 0.1% | 0.3% | ||
| Q3 25 | 0.1% | 1.0% | ||
| Q2 25 | 0.2% | 0.6% | ||
| Q1 25 | 0.0% | 0.6% | ||
| Q4 24 | 0.0% | 1.7% | ||
| Q3 24 | 0.0% | 4.0% | ||
| Q2 24 | 0.1% | 0.5% | ||
| Q1 24 | 0.0% | 4.3% |
现金转化率AKBARDI
| Q4 25 | — | — | ||
| Q3 25 | 52.05× | — | ||
| Q2 25 | 90.47× | — | ||
| Q1 25 | -2.22× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AKBA
| Auryxia | $48.1M | 84% |
| Vafseo | $6.2M | 11% |
| License Collaboration And Other Revenue | $3.3M | 6% |
RDI
| Cinema Exhibition Segment | $46.9M | 93% |
| Real Estate Revenue | $3.4M | 7% |
